Editas Medicine Company Profile (NASDAQ:EDIT)

About Editas Medicine (NASDAQ:EDIT)

Editas Medicine logoEditas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EDIT
  • CUSIP: N/A
  • Web: www.editasmedicine.com
Capitalization:
  • Market Cap: $953.67 million
  • Outstanding Shares: 35,840,000
Average Prices:
  • 50 Day Moving Avg: $20.92
  • 200 Day Moving Avg: $20.92
  • 52 Week Range: $12.43 - $28.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.31
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.64 million
  • Price / Sales: 134.21
  • Book Value: $3.76 per share
  • Price / Book: 5.62
Profitability:
  • EBIDTA: ($114,840,000.00)
  • Net Margins: -2,091.36%
  • Return on Equity: -67.75%
  • Return on Assets: -38.19%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 6.74%
  • Quick Ratio: 6.74%
Misc:
  • Average Volume: 1.29 million shs.
  • Beta: 4.78
  • Short Ratio: 13.74
 

Frequently Asked Questions for Editas Medicine (NASDAQ:EDIT)

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. The business earned $3.10 million during the quarter, compared to analysts' expectations of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The company's quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) earnings per share. View Editas Medicine's Earnings History.

When will Editas Medicine make its next earnings announcement?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Editas Medicine.

Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?

8 brokers have issued 1 year price targets for Editas Medicine's shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Editas Medicine's stock price to reach $26.75 in the next year. View Analyst Ratings for Editas Medicine.

What are analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:

  • 1. Cann analysts commented, "Editas’ loss per share was $0.65, compared to our estimated loss of $1.01. This was the result of higher than expected collaborative revenue, lower than estimated operating expenses and higher than estimated shares outstanding." (8/10/2017)
  • 2. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (7/18/2017)
  • 3. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)
  • 4. Cowen and Company analysts commented, "Today Editas partnered its ophthalmology CRISPR programs with Allergan for $90MM." (3/15/2017)
  • 5. Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)

Who are some of Editas Medicine's key competitors?

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:

  • Katrine S. Bosley, President, Chief Executive Officer, Director
  • Andrew A. F. Hack, Chief Financial Officer
  • Charles Albright, Chief Scientific Officer
  • Gerald Cox, Chief Medical Officer
  • Andrew Hirsch, Director
  • Akshay K. Vaishnaw M.D., Ph.D., Director
  • Kevin J. Bitterman Ph.D., Independent Director
  • Alexis Borisy, Independent Director
  • Douglas G. Cole M.D., Independent Director

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who owns Editas Medicine stock?

Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (11.70%), Flagship Pioneering Inc. (8.29%), Vanguard Group Inc. (5.35%), Capital World Investors (4.32%), State Street Corp (1.31%) and ARK Investment Management LLC (1.25%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Gerald Frank Cox, James E Flynn, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Who sold Editas Medicine stock? Who is selling Editas Medicine stock?

Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, TD Asset Management Inc., Cim Investment Mangement Inc. and Victory Capital Management Inc.. Company insiders that have sold Editas Medicine stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Katrine Bosley, Kevin Bitterman and Polaris Venture Management Co. View Insider Buying and Selling for Editas Medicine.

Who bought Editas Medicine stock? Who is buying Editas Medicine stock?

Editas Medicine's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, ARK Investment Management LLC, Northern Trust Corp, Vanguard Group Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Nisa Investment Advisors LLC and Greenwoods Asset Management Ltd. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and James E Flynn. View Insider Buying and Selling for Editas Medicine.

How do I buy Editas Medicine stock?

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of Editas Medicine stock can currently be purchased for approximately $21.12.


MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $26.75 (26.66% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Barclays PLCInitiated CoverageOverweight$19.69 -> $28.00MediumView Rating Details
8/9/2017J P Morgan Chase & CoSet Price TargetHold$27.00HighView Rating Details
8/10/2017CannReiterated RatingHoldHighView Rating Details
7/18/2017Oppenheimer Holdings, Inc.Market PerformN/AView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageHold -> Hold$17.00HighView Rating Details
3/27/2017Chardan CapitalInitiated CoverageBuy -> BuyHighView Rating Details
3/15/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
2/15/2017Jefferies Group LLCReiterated RatingBuy$35.00N/AView Rating Details
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00N/AView Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Editas Medicine (NASDAQ:EDIT)
Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)
Earnings History by Quarter for Editas Medicine (NASDAQ EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.60)N/AView Earnings Details
8/9/2017Q2 2017($0.64)($0.65)$2.20 million$3.10 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.62)($0.85)$1.00 million$0.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.62)($1.10)$1.11 million$0.90 millionViewListenView Earnings Details
11/7/2016Q3($0.64)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
8/9/2016Q2($0.54)($0.54)$3.52 million$3.39 millionViewListenView Earnings Details
5/16/2016Q116($0.23)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)$0.79 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
2017 EPS Consensus Estimate: ($3.07)
2018 EPS Consensus Estimate: ($4.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.70)($0.70)($0.70)
Q3 20173($0.75)($0.67)($0.72)
Q4 20173($1.40)($0.77)($0.99)
Q1 20181($0.98)($0.98)($0.98)
Q2 20181($0.85)($0.85)($0.85)
Q3 20181($0.89)($0.89)($0.89)
Q4 20181($1.66)($1.66)($1.66)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Editas Medicine (NASDAQ:EDIT)
Insider Ownership Percentage: 19.40%
Institutional Ownership Percentage: 69.98%
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Katrine BosleyInsiderSell16,666$20.33$338,819.78View SEC Filing  
9/1/2017Katrine BosleyCEOSell10,000$20.42$204,200.00View SEC Filing  
8/11/2017Katrine BosleyInsiderSell16,666$20.02$333,653.32View SEC Filing  
6/2/2017Boris NikolicDirectorBuy35,000$14.07$492,450.00View SEC Filing  
6/2/2017Gerald Frank CoxInsiderBuy4,000$14.15$56,600.00View SEC Filing  
5/22/2017Kevin BittermanDirectorSell1,000,000$17.00$17,000,000.00View SEC Filing  
3/15/2017Alexandra GlucksmannCOOSell1,000$26.41$26,410.00View SEC Filing  
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.00View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.00View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Editas Medicine (NASDAQ:EDIT)
Latest Headlines for Editas Medicine (NASDAQ:EDIT)
Source:
DateHeadline
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 25 at 2:38 AM
streetinsider.com logoForm 8-K Editas Medicine, Inc. For: Sep 18 - StreetInsider.com
www.streetinsider.com - September 23 at 3:18 AM
americanbankingnews.com logo Brokerages Anticipate Editas Medicine, Inc. (EDIT) Will Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - September 21 at 12:20 AM
marketwatch.com logoBiotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte
www.marketwatch.com - September 15 at 6:41 PM
reuters.com logoBRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10
www.reuters.com - September 12 at 11:59 PM
globenewswire.com logoEditas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type ... - GlobeNewswire (press release)
globenewswire.com - September 12 at 6:55 PM
finance.yahoo.com logoEditas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
finance.yahoo.com - September 12 at 6:55 PM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Coverage Initiated by Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:52 PM
fool.com logoWhy Gene-Editing Pioneer Editas Skyrocketed 28.8% in August - Motley Fool
www.fool.com - September 9 at 4:58 AM
nasdaq.com logoAdverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors
www.nasdaq.com - September 7 at 6:15 PM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) CEO Sells $204,200.00 in Stock
www.americanbankingnews.com - September 6 at 8:50 PM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Insider Sells $338,819.78 in Stock
www.americanbankingnews.com - September 6 at 8:28 PM
finance.yahoo.com logoEditas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 7:48 PM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 31 at 2:46 AM
finance.yahoo.com logoThis Stock Could Be the Tesla of Healthcare
finance.yahoo.com - August 28 at 3:24 AM
nasdaq.com logoEditas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% - Nasdaq
www.nasdaq.com - August 16 at 6:33 PM
americanbankingnews.com logo$2.55 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter
www.americanbankingnews.com - August 16 at 2:32 AM
americanbankingnews.com logoInsider Selling: Editas Medicine, Inc. (EDIT) Insider Sells 16,666 Shares of Stock
www.americanbankingnews.com - August 14 at 11:10 PM
finance.yahoo.com logo[$$] Gormley's Take: Biotech Companies Are Steering Clear of Gene Editing's Ethical Concerns
finance.yahoo.com - August 14 at 6:29 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Editas Medicine, Inc. Lifted by Oppenheimer Holdings (EDIT)
www.americanbankingnews.com - August 14 at 3:18 AM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) to Post Q3 2017 Earnings of ($0.75) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - August 14 at 3:18 AM
finance.yahoo.com logoEdited Transcript of EDIT earnings conference call or presentation 9-Aug-17 9:00pm GMT
finance.yahoo.com - August 10 at 7:26 PM
americanbankingnews.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - August 9 at 11:58 PM
streetinsider.com logoEditas Medicine (EDIT) to Receive $2.5M for Milestone Under Juno Therapeutics Collaboration
www.streetinsider.com - August 9 at 11:23 PM
globenewswire.com logoEditas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:21 PM
finance.yahoo.com logoEditas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
finance.yahoo.com - August 9 at 6:21 PM
finance.yahoo.com logoEditas Medicine Announces Second Quarter 2017 Results and Update
finance.yahoo.com - August 9 at 6:21 PM
finance.yahoo.com logoEditas reports 2Q loss
finance.yahoo.com - August 9 at 6:21 PM
fool.com logoHere's Why Editas Medicine Rose as Much as 15.9% Monday - Motley Fool
www.fool.com - August 9 at 3:58 AM
finance.yahoo.com logoHere's Why Editas Medicine Rose as Much as 15.9% Monday
finance.yahoo.com - August 8 at 5:55 PM
finance.yahoo.com logoEditas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
finance.yahoo.com - August 7 at 6:27 PM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 6 at 7:10 AM
thestreet.com logoPacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
www.thestreet.com - August 3 at 12:04 AM
prnewswire.com logoBiotech Stock Performance Review -- Celgene, Cempra, Editas Medicine, and Epizyme - PR Newswire (press release)
www.prnewswire.com - July 31 at 5:55 PM
finance.yahoo.com logoEditas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : July 31, 2017
finance.yahoo.com - July 31 at 5:55 PM
americanbankingnews.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Expected to Announce Quarterly Sales of $2.88 Million
www.americanbankingnews.com - July 29 at 7:27 AM
americanbankingnews.com logo Analysts Expect Editas Medicine, Inc. (EDIT) to Post -$0.64 EPS
www.americanbankingnews.com - July 27 at 2:26 PM
finance.yahoo.com logoETFs with exposure to Editas Medicine, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:56 PM
americanbankingnews.com logoOppenheimer Holdings Comments on Editas Medicine, Inc.'s FY2017 Earnings (EDIT)
www.americanbankingnews.com - July 20 at 10:35 AM
americanbankingnews.com logoEditas Medicine, Inc. (EDIT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 18 at 10:20 PM
americanbankingnews.com logoCann Initiates Coverage on Editas Medicine, Inc. (NASDAQ:EDIT)
www.americanbankingnews.com - July 17 at 7:15 PM
americanbankingnews.com logoSunTrust Banks, Inc. Initiates Coverage on Editas Medicine, Inc. (EDIT)
www.americanbankingnews.com - July 16 at 5:14 PM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For July 14, 2017 - Benzinga
www.benzinga.com - July 14 at 3:09 PM
finance.yahoo.com logoETFs with exposure to Editas Medicine, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:09 PM
americanbankingnews.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 12 at 10:11 PM
americanbankingnews.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM
fool.com logoHere's Why Editas Medicine Inc. Bounced Up 20% in June -- The ... - Motley Fool
www.fool.com - July 12 at 12:18 AM
finance.yahoo.com logoEditas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : July 11, 2017
finance.yahoo.com - July 11 at 7:18 PM
finance.yahoo.com logoHere's Why Editas Medicine Inc. Bounced Up 20% in June
finance.yahoo.com - July 11 at 7:18 PM
finance.yahoo.com logoEditas Medicine, Inc. – Value Analysis (NASDAQ:EDIT) : July 3, 2017
finance.yahoo.com - July 3 at 6:01 PM

Social

Chart

Editas Medicine (EDIT) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff